Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Angiogenesis inhibitors in clinical development for lung cancer.
Herbst RS, Hidalgo M, Pierson AS, Holden SN, Bergen M, Eckhardt SG. Herbst RS, et al. Among authors: eckhardt sg. Semin Oncol. 2002 Feb;29(1 Suppl 4):66-77. doi: 10.1053/sonc.2002.31527. Semin Oncol. 2002. PMID: 11894016 Review.
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium.
Eckhardt SG, Burris HA, Eckardt JR, Weiss G, Rodriguez G, Rothenberg M, Rinaldi D, Barrington R, Kuhn JG, Masuo K, Sudo K, Atsumi R, Oguma T, Higashi L, Fields S, Smetzer L, Von Hoff DD. Eckhardt SG, et al. Ann Oncol. 1996 Jul;7(5):491-6. doi: 10.1093/oxfordjournals.annonc.a010638. Ann Oncol. 1996. PMID: 8839904 Free article. Clinical Trial.
Angiogenesis inhibitors as cancer therapy.
Eckhardt SG. Eckhardt SG. Hosp Pract (1995). 1999 Jan 15;34(1):63-8, 77-9, 83-4. doi: 10.3810/hp.1999.01.124. Hosp Pract (1995). 1999. PMID: 9931577
Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies.
Hidalgo M, Villalona-Calero MA, Eckhardt SG, Drengler RL, Rodriguez G, Hammond LA, Diab SG, Weiss G, Garner AM, Campbell E, Davidson K, Louie A, O'Neil JD, von Borstel R, Von Hoff DD, Rowinsky EK. Hidalgo M, et al. Among authors: eckhardt sg. J Clin Oncol. 2000 Jan;18(1):167-77. doi: 10.1200/JCO.2000.18.1.167. J Clin Oncol. 2000. PMID: 10623707 Clinical Trial.
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies.
Rowinsky EK, Humphrey R, Hammond LA, Aylesworth C, Smetzer L, Hidalgo M, Morrow M, Smith L, Garner A, Sorensen JM, Von Hoff DD, Eckhardt SG. Rowinsky EK, et al. Among authors: eckhardt sg. J Clin Oncol. 2000 Jan;18(1):178-86. doi: 10.1200/JCO.2000.18.1.178. J Clin Oncol. 2000. PMID: 10623708 Clinical Trial.
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK. Eckhardt SG, et al. J Clin Oncol. 2000 Dec 15;18(24):4086-97. doi: 10.1200/JCO.2000.18.24.4086. J Clin Oncol. 2000. PMID: 11118470
362 results